| Prev Close | 90.70 |
| Day Low/High | 90.05 / 91.70 |
| 52 Wk Low/High | 62.55 / 97.86 |
| Avg Volume | 13.15M |
AbbVie Inc. (ABBV)
91.04
NYSE : Health Technology
| Exchange | NYSE |
| Shares Outstanding | 1.76B |
| Market Cap | 159.84B |
| EPS | 5.30 |
| P/E Ratio | 16.00 |
| Div & Yield | 4.72 (4.86%) |
Biotech Just Got Trumped
But the 3% drop in the sector yesterday is clearly an overreaction to Trump's comments.
Top 5 Dividend Stocks to Buy Now for 2017
Here is a look at some stocks that are poised for excellent dividend returns in 2017.
Expect Some Big-Cap Biotech Love in 2017
We touched briefly on housing in our first post this morning. There are still some cheap home-building stocks if the housing market continues to improve, which I expect as I believe economic growth will pick up in 2017. I have done well with this se...
AbbVie Needs a Nudge to Get the Bull Going Again
Overall, the next move for ABBV looks like it will be to the upside.
Bullish and Bearish Chart Reversals
What stocks have changed direction in the past week.
How to Play Rising Treasury Yields
Check out these 15 stocks that boast solid dividend yields and are growing earnings.
Cramer: How Bad Was Today? Let Us Count the Ways
Today there was a virtual vacuum of good news in the stock market.
Cramer: With the Election Coming, Valeant's Problem Is Increasing
We have to ask: where is the cash flow to pay off the debt, if any important prices are rolled back?
AbbVie Q3 Revenue Misses, Shares Decline
Shares of AbbVie were lower Friday after posting disappointing third-quarter revenue.
Jim Cramer Explains Why Health Care Stocks are Getting Slammed on Wall Street Today
McKesson's disappointing earnings report ignited a selloff in health care stocks, and Jim Cramer says investors are questioning the sector's future.
Bullish and Bearish Reversals for the Week
Technology stocks dominate the bearish ledger this week.
Time For Selective Purchases of Health-Care Stocks
With Clinton apparently headed for victory, worries about her being a threat to health-care stocks have peaked.
These Dogs Are Becoming Cool Cats
The dreck of the first half will be the gems of year end.
5 Healthy Pharma and Biotech Plays
These stocks look good as seasonal volatility sets in.
Dive Safely Into These 12 Dividend Payers
If and when interest rates go up, this basket of stocks should continue to do well.
Cramer: The Answer to This Market: Part 1
The leadership is quite stark.
TG Therapeutics Looks Like a Healthy Play
Small biotech tanked on weak earnings, but still seems promising.
Gilead Draws Buyers as Prospect of Business Divide Rises, Jim Cramer Says
RBC Capital analysts say splitting the company into two distinct businesses would free 'trapped value' on drug treatments.
Closing Bell: AbbVie Sues Amgen; S&P 500, Nasdaq at New Records
Stocks secure robust gains after the latest labor market snapshot breezes past expectations.
Gilead and Teva: Off-the-Charts Cheap
Rarely do investors get to buy these types of quality businesses at such discounted prices.
It's 'All Systems Go' for Biotech
The sector seems to be rebounding after tumbling by more than 40%.
Portfolio Roundup: Humira Helps Buoy AbbVie Shares
The drug maker continued to rally Monday.
Grasping for Growth in a Broken Economy
The bifurcation can be seen just by looking at Apple's recent results.
AbbVie Shares Rise on Revenue Jump
Shares of AbbVie were up Friday after the company reported a big jump in revenue.
AbbVie Is Still Pointed Up, for Now
Consider raising your sell stop protection to a close below $61.
Trending Tickers: BUD, ABBV, SRCL, EXPE
The Anheuser-Busch InBev and SABMiller deal is another step closer to completion.
Buy Gilead Sciences While It's Wallowing
It's too cheap for a biotech giant with years of patent protection for key products and great cash flow.
